vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and DLH Holdings Corp. (DLHC). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $68.9M, roughly 1.1× DLH Holdings Corp.). DLH Holdings Corp. runs the higher net margin — -1.9% vs -9.6%, a 7.7% gap on every dollar of revenue. On growth, Bioceres Crop Solutions Corp. posted the faster year-over-year revenue change (-16.8% vs -24.1%). Over the past eight quarters, Bioceres Crop Solutions Corp.'s revenue compounded faster (-8.4% CAGR vs -17.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

DLH Holdings Corp. is a U.S.-based provider of technology-enabled healthcare, logistics, engineering, and mission support services primarily serving federal government agencies including the Department of Veterans Affairs, Department of Defense, and Department of Health and Human Services, as well as select state and local government clients across core public service segments.

BIOX vs DLHC — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.1× larger
BIOX
$77.6M
$68.9M
DLHC
Growing faster (revenue YoY)
BIOX
BIOX
+7.3% gap
BIOX
-16.8%
-24.1%
DLHC
Higher net margin
DLHC
DLHC
7.7% more per $
DLHC
-1.9%
-9.6%
BIOX
Faster 2-yr revenue CAGR
BIOX
BIOX
Annualised
BIOX
-8.4%
-17.4%
DLHC

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BIOX
BIOX
DLHC
DLHC
Revenue
$77.6M
$68.9M
Net Profit
$-7.4M
$-1.3M
Gross Margin
46.8%
Operating Margin
9.3%
2.1%
Net Margin
-9.6%
-1.9%
Revenue YoY
-16.8%
-24.1%
Net Profit YoY
-20.2%
-218.7%
EPS (diluted)
$-0.12
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
DLHC
DLHC
Q4 25
$68.9M
Q3 25
$77.6M
$81.2M
Q2 25
$83.3M
Q1 25
$60.6M
$89.2M
Q4 24
$98.8M
$90.8M
Q3 24
$93.3M
$96.4M
Q2 24
$100.7M
Q1 24
$84.0M
$101.0M
Net Profit
BIOX
BIOX
DLHC
DLHC
Q4 25
$-1.3M
Q3 25
$-7.4M
$-920.0K
Q2 25
$289.0K
Q1 25
$-1.6M
$878.0K
Q4 24
$605.2K
$1.1M
Q3 24
$-6.2M
$2.3M
Q2 24
$1.1M
Q1 24
$9.8M
$1.8M
Gross Margin
BIOX
BIOX
DLHC
DLHC
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Q1 24
50.8%
Operating Margin
BIOX
BIOX
DLHC
DLHC
Q4 25
2.1%
Q3 25
9.3%
2.8%
Q2 25
4.5%
Q1 25
1.5%
5.7%
Q4 24
14.5%
6.2%
Q3 24
2.5%
6.6%
Q2 24
5.7%
Q1 24
15.7%
5.9%
Net Margin
BIOX
BIOX
DLHC
DLHC
Q4 25
-1.9%
Q3 25
-9.6%
-1.1%
Q2 25
0.3%
Q1 25
-2.6%
1.0%
Q4 24
0.6%
1.2%
Q3 24
-6.6%
2.4%
Q2 24
1.1%
Q1 24
11.6%
1.8%
EPS (diluted)
BIOX
BIOX
DLHC
DLHC
Q4 25
$-0.09
Q3 25
$-0.12
$-0.07
Q2 25
$0.02
Q1 25
$-0.02
$0.06
Q4 24
$0.00
$0.08
Q3 24
$-0.10
$0.16
Q2 24
$0.08
Q1 24
$0.14
$0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
DLHC
DLHC
Cash + ST InvestmentsLiquidity on hand
$15.5M
$257.0K
Total DebtLower is stronger
$133.5M
Stockholders' EquityBook value
$288.3M
$112.2M
Total Assets
$734.9M
$283.5M
Debt / EquityLower = less leverage
1.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
DLHC
DLHC
Q4 25
$257.0K
Q3 25
$15.5M
$125.0K
Q2 25
$194.0K
Q1 25
$38.5M
$196.0K
Q4 24
$29.2M
$451.0K
Q3 24
$32.3M
$342.0K
Q2 24
$423.0K
Q1 24
$16.4M
$238.0K
Total Debt
BIOX
BIOX
DLHC
DLHC
Q4 25
$133.5M
Q3 25
$128.0M
Q2 25
$138.3M
Q1 25
$147.3M
Q4 24
$162.2M
Q3 24
$149.4M
Q2 24
$160.9M
Q1 24
$164.8M
Stockholders' Equity
BIOX
BIOX
DLHC
DLHC
Q4 25
$112.2M
Q3 25
$288.3M
$113.0M
Q2 25
$113.7M
Q1 25
$345.0M
$112.8M
Q4 24
$346.3M
$111.4M
Q3 24
$346.0M
$110.1M
Q2 24
$108.6M
Q1 24
$348.5M
$106.8M
Total Assets
BIOX
BIOX
DLHC
DLHC
Q4 25
$283.5M
Q3 25
$734.9M
$290.7M
Q2 25
$299.3M
Q1 25
$798.2M
$306.6M
Q4 24
$835.2M
$325.0M
Q3 24
$827.3M
$314.4M
Q2 24
$325.0M
Q1 24
$836.1M
$325.9M
Debt / Equity
BIOX
BIOX
DLHC
DLHC
Q4 25
1.19×
Q3 25
1.13×
Q2 25
1.22×
Q1 25
1.31×
Q4 24
1.46×
Q3 24
1.36×
Q2 24
1.48×
Q1 24
1.54×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
DLHC
DLHC
Operating Cash FlowLast quarter
$14.4M
$-4.8M
Free Cash FlowOCF − Capex
$-4.8M
FCF MarginFCF / Revenue
-7.0%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$29.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
DLHC
DLHC
Q4 25
$-4.8M
Q3 25
$14.4M
$10.7M
Q2 25
$9.6M
Q1 25
$23.3M
$14.5M
Q4 24
$-5.4M
$-11.5M
Q3 24
$5.2M
$12.4M
Q2 24
$4.6M
Q1 24
$-17.4M
$5.2M
Free Cash Flow
BIOX
BIOX
DLHC
DLHC
Q4 25
$-4.8M
Q3 25
$10.7M
Q2 25
$9.4M
Q1 25
$14.0M
Q4 24
$-12.1M
Q3 24
$12.2M
Q2 24
$4.5M
Q1 24
$4.9M
FCF Margin
BIOX
BIOX
DLHC
DLHC
Q4 25
-7.0%
Q3 25
13.1%
Q2 25
11.2%
Q1 25
15.6%
Q4 24
-13.3%
Q3 24
12.7%
Q2 24
4.4%
Q1 24
4.9%
Capex Intensity
BIOX
BIOX
DLHC
DLHC
Q4 25
0.1%
Q3 25
0.0%
Q2 25
0.3%
Q1 25
0.6%
Q4 24
0.6%
Q3 24
0.2%
Q2 24
0.2%
Q1 24
0.3%
Cash Conversion
BIOX
BIOX
DLHC
DLHC
Q4 25
Q3 25
Q2 25
33.12×
Q1 25
16.52×
Q4 24
-8.85×
-10.35×
Q3 24
5.42×
Q2 24
4.06×
Q1 24
-1.78×
2.89×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIOX
BIOX

Segment breakdown not available.

DLHC
DLHC

Sales Channel Directly To Consumer$64.5M94%
Sales Channel Through Intermediary$4.4M6%

Related Comparisons